Pharmacokinetics and Safety, Tolerability of DWJ211in Healthy Volunteers

A Randomized, Open-label, Parallel Design Clinical Trial to Evaluate the Safety/Tolerability and Pharmacokinetic of DWJ211 in Healthy Volunteers

This is a randomized, open-label, parallel design Phase I clinical trial to evaluate the safety/tolerability and pharmacokinetic of DWJ211 in healthy volunteers

Inclusion Criteria:

• Healthy adult aged between 19 and 65 at screening
• Those whose BMI is less than 40kg/m2
• Subject who will agree with the no treatment(liposuction or surgery, obesity treatment)
• Those who are adequate to be subjects in this study upon judgment of the investigator after physical examination, clinical laboratory test, examination by interview, etc

Exclusion Criteria:

• Those who have clinical significant liver, kidney, nervous system, respiratory, endocrine, hematology and oncology, cardiovascular, urinary, and mental diseases or past history
• History of any intervention to treat Submental fat or abdominal fat
• History or current symptoms of dysphagia
• History of trauma associated with the chin or neck or abdominal areas that in the judgement of the investigator may affect evaluation of safety or efficacy of treatment